Shares Magazine
2.17p-0.40 (-15.40%)31 Dec 2024, 09:33
Jump to:
Synairgen PLC Fundamentals
| Company Name | Synairgen PLC | Last Updated | 2024-12-31 |
|---|---|---|---|
| Industry | Biotechnology | Sector | Healthcare |
| Shares in Issue | 280.548 m | Market Cap | £6.09 m |
| PE Ratio | 0.00 | Dividend per Share | 0 |
| Dividend Yield | 0 | Dividend Cover | 0 |
| EPS | -£0.03 | EPS Growth (%) | 0 |
| PEG | 0 | DPS Growth (%) | 0 |
| Debt Ratio | 0 | Debt Equity Ratio | 0 |
| Asset Equity Ratio | 1.1127 | Cash Equity Ratio | 0.8985 |
| Quick Ratio | 8.2319 | Current Ratio | 9.76 |
| Price To Book Value | 0.7526 | ROCE | 0 |
Synairgen PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Synairgen PLC Company Financials
| Assets | 2023 | 2022 | 2021 |
|---|---|---|---|
| Tangible Assets | £26,000.00 | £86,000.00 | £173,000.00 |
| Intangible Assets | £102,000.00 | £44,000.00 | £53,000.00 |
| Investments | 0 | 0 | 0 |
| Total Fixed Assets | £128,000.00 | £130,000.00 | £226,000.00 |
| Stocks | 0 | 0 | 0 |
| Debtors | £674,000.00 | £1.08 m | £974,000.00 |
| Cash & Equivalents | £12.02 m | £19.68 m | £33.83 m |
| Other Assets | 0 | 0 | 0 |
| Total Assets | £14.22 m | £23.53 m | £44.64 m |
| Liabilities | 2023 | 2022 | 2021 |
|---|---|---|---|
| Creditors within 1 year | £1.56 m | £3.25 m | £7.64 m |
| Creditors after 1 year | 0 | 0 | 0 |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | £1.56 m | £3.25 m | £7.64 m |
| Net assets | £12.66 m | £20.27 m | £37.00 m |
| Equity | 2023 | 2022 | 2021 |
|---|---|---|---|
| Called up share capital | £2.01 m | £2.01 m | £2.01 m |
| Share Premium | £125.25 m | £125.25 m | £125.25 m |
| Profit / Loss | -£9.66 m | -£20.09 m | -£57.86 m |
| Other Equity | £12.66 m | £20.27 m | £37.00 m |
| Preference & Minorities | 0 | 0 | 0 |
| Total Capital Employed | £12.66 m | £20.27 m | £37.00 m |
| Ratios | 2023 | 2022 | 2021 |
|---|---|---|---|
| Debt Ratio | 0 | 0 | 0 |
| Debt-to-Equity | 0 | 0 | 0 |
| Assets / Equity | 1.1127 | 1.1127 | 1.1127 |
| Cash / Equity | 0.8985 | 0.8985 | 0.8985 |
| EPS | -£0.03 | -£0.06 | -£0.18 |
| Cash Flow | 2023 | 2022 | 2021 |
|---|---|---|---|
| Cash from operating activities | -£8.22 m | -£14.29 m | -£41.02 m |
| Cashflow before financing | -£8.22 m | -£14.29 m | -£41.13 m |
| Increase in Cash | -£5.41 m | -£17.90 m | -£41.15 m |
| Income | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | 0 | 0 | 0 |
| Cost of sales | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 |
| Operating Profit | -£10.29 m | -£20.30 m | -£57.87 m |
| Pre-Tax profit | -£9.66 m | -£20.09 m | -£57.86 m |
Synairgen PLC Company Background
| Sector | Healthcare |
|---|---|
| Activities | Synairgen PLC is a United Kingdom-based respiratory drug discovery and development company. The company is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in areas, including severe asthma,kidney fibrosis, cardiac fibrosis, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis. The company's Programmes include SNG001, SG016, SG018, and others. |
| Latest Interim Date | 26 Sep 2024 |
| Latest Fiscal Year End Date | 27 Jun 2024 |
Synairgen PLC Directors
| Appointed | Name | Position |
|---|---|---|
| 2022-12-01 | Mr. Iain Peter Murray Buchanan | Non-Executive Director |
| 2024-10-10 | Mr. Simon James Blouet Shaw | Non-Executive Director,Chairman |
| 2024-06-27 | Dr. David Bruce Campbell | Non-Executive Director |
| 2024-06-27 | Mr. Richard James Marsden | Executive Director,Chief Executive Officer |
| 2024-06-27 | Professor Stephen Townley Holgate, CBE | Non-Executive Director |
| 2024-06-27 | Dr. Phillip David Monk | Executive Director,Chief Scientific Officer |
| 2019-06-03 | Mr. Paul Hugh Anthony Clegg | Non-Executive Director |
| 2023-11-03 | Mr. John Christopher Ward | Executive Director,Chief Financial Officer and Company Secretary |
| 2024-06-27 | Mr. Joseph Tregonning Colliver | Executive Director,Chief Financial Officer |
Synairgen PLC Contact Details
| Company Name | Synairgen PLC |
|---|---|
| Address | Mailpoint 810, Level F, South Block, Southampton Gen Hospital, Tremona Road, Southampton, SO16 6YD |
| Telephone | +44 2380512800 |
| Website | https://www.synairgen.com |
Synairgen PLC Advisors
| Solicitor | Fladgate LLP |
|---|---|
| Phone | +44 2030367000 |
| Fax | +44 2030367600 |
| Registrar | Capita Asset Services |
|---|---|
| Phone | +44 8716640300 |
| Fax | +44 2086392342 |
| Financial PR Adviser | Consilium Strategic Communications |
|---|---|
| Phone | +44 2037095700 |
| Remuneration Consultant | FIT Remuneration Consultants LLP |
|---|---|
| Phone | +44 2070311111 |
| Nominated Adviser | FinnCap |
|---|---|
| Phone | +44 2072200500 |
| Fax | +44 2076001659 |
| Stockbroker | FinnCap |
|---|---|
| Phone | +44 2072200500 |
| Fax | +44 2076001659 |
| Auditor | BDO LLP |
|---|---|
| Phone | +44 2380881700 |
| Fax | +44 2380881701 |
| Bank | HSBC Bank PLC |
|---|
Most Read
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
| Company | Price | % Chg |
|---|---|---|
| Sthree PLC | 290.50 | 3.20 |
| Oxford Nanopore Technologies PLC | 128.81 | 2.80 |
| Kainos Group PLC | 799.00 | 2.70 |
| Apax Global Alpha Limited | 142.60 | 2.59 |
| Foresight Environmental Infrastructure Limited | 73.62 | 2.39 |
| Bridgepoint Group PLC | 357.40 | 2.35 |
Fallers
| Company | Price | % Chg |
|---|---|---|
| W.A.G Payment Solutions PLC | 78.00 | -2.50 |
| Worldwide Healthcare Trust PLC | 314.60 | -1.22 |
| Goodwin PLC | 7,797.00 | -1.05 |
| Smith (Ds) PLC | 536.50 | -1.01 |
| Premier Foods PLC | 184.02 | -0.96 |
| Ashtead Group PLC | 4,886.72 | -0.90 |